BioCentury
ARTICLE | Clinical News

Vical discontinues a Phase II Leuvectin trial

April 19, 2001 7:00 AM UTC

VICL discontinued its Phase II trial of Leuvectin, a lipid formulation of DNA encoding interleukin-2 (IL-2), in patients with metastatic kidney cancer based on an interim analysis of 37 patients in wh...